Skip to content

A prospective clinical study of ultrasound-guided cryoablation in the treatment of primary hyperthyroidism

A prospective clinical study of ultrasound-guided cryoablation in the treatment of primary hyperthyroidism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118948
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-02-13
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hyperthyroidism

Interventions

Control group:Use conventional anti-thyroid drugs for treatment (specify the drug name, such as methimazole, propylthiouracil, etc.). Based on the patients age, weight, and thyroid function index leve

Sponsors

Chinese People's Liberation Army General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. A clearly diagnosed primary hyperthyroidism. 2. The cause of hyperthyroidism is clearly identified as Graves' disease or nodular lesion. The nodules are hyperfunctioning adenomas and toxic multinodular goiter. 3. The characteristics of the nodules meet the ablation conditions: the size of the nodules is moderate: usually ranging from 1 to 4 cm; overly large nodules may require multiple treatments or are not suitable for ablation; the location of the nodules: easy to puncture, and there is sufficient safety distance from surrounding important structures, or protective measures such as water isolation can be taken; the nature of the nodules: excluded the possibility of malignancy through fine needle aspiration biopsy (FNA) or clinical assessment. 4. Candidates for surgery.

Exclusion criteria

Exclusion criteria: 1. The patient was unable to tolerate it due to factors such as age, underlying diseases, and surgical risks. 2. Secondary hyperthyroidism. 3. The nature of the nodules is questionable or has been diagnosed as malignant. 4. Coagulation dysfunction, local or systemic infection, dysfunction of important organs, mental illness, or inability to cooperate with treatment, etc. 5. Pregnant or lactating women. 6. There is significant vascular or nerve adhesion in the treatment area.

Design outcomes

Primary

MeasureTime frame
Thyroid size ;Thyroid function;Target nodule shrinkage rate;

Secondary

MeasureTime frame
The degree of improvement of clinical symptoms;Complications;Treatment parameters;

Countries

China

Contacts

Public ContactLuo Yukun

Chinese People's Liberation Army General Hospital

lyk301@163.com+86 10 6693 9511

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026